Meeting Abstract

Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma


Authors listFenk, Roland; Baier, Julia; Giagounidis, Aristoteles; Rummel, Mathias J.; Kroeger, Nicolaus; Strapatsas, Tobias; Dienst, Ariane; Zipperer, Esther; Nachtkamp, Kathrin; Burchardt, Alexander; Schroeder, Thomas; Galonska, Lars; Gattermann, Norbert; Haas, Rainer; Kobbe, Guido

Publication year2012

JournalBlood

Volume number120

Issue number21

ISSN0006-4971

eISSN1528-0020

DOI Linkhttps://doi.org/10.1182/blood.V120.21.1982.1982

Conference54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

PublisherAmerican Society of Hematology (ASH Publications)



Citation Styles

Harvard Citation styleFenk, R., Baier, J., Giagounidis, A., Rummel, M., Kroeger, N., Strapatsas, T., et al. (2012) Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma, Blood, 120(21). https://doi.org/10.1182/blood.V120.21.1982.1982

APA Citation styleFenk, R., Baier, J., Giagounidis, A., Rummel, M., Kroeger, N., Strapatsas, T., Dienst, A., Zipperer, E., Nachtkamp, K., Burchardt, A., Schroeder, T., Galonska, L., Gattermann, N., Haas, R., & Kobbe, G. (2012). Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma. Blood. 120(21). https://doi.org/10.1182/blood.V120.21.1982.1982


Last updated on 2025-01-04 at 23:31